Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2Bi-Armed T Cells and IL-2 for Her2-positive Digestive System Neoplasms
NCT02662348Phase 1Unknown
- Start
- Feb 2016
- Primary completion
- Nov 2017
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HER2Bi-armed activated T cells in esophageal cancer, gastric cancer (GC), pancreatic cancer (PC) and 3 more. Primary endpoint: Safety as measured by local and systemic toxicities at 1 year. Status: unknown.
02
Drugs
HER2Bi-armed activated T cells
03
Conditions
esophageal cancergastric cancer (GC)pancreatic cancer (PC)liver cancergallbladder cancer
Beyond the preview
Go deeper on NCT02662348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662348.